Clinical trial
Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients…
NCT00016237 · EMD Serono, Industry · Completed
Key facts
| NCT number | NCT00016237 |
|---|---|
| Title | Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment |
| Official title | Phase I Dose-Escalation Study of the Pharmacokinetic, Safety, Tolerability, and Biologic Activity of huKS-IL-2 Administered Daily as a 1-Hour Intravenous Infusion for Five Consecutive Days for Treatment of Refractory Epithelial Cancer |
| Lead sponsor | EMD Serono, Industry |
| Collaborators | National Cancer Institute (NCI) NIH Memorial Sloan Kettering Cancer Center |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Bladder Cancer, Kidney Cancer, Lung Cancer |
| Intervention type | Biological |
| Interventions | tucotuzumab celmoleukin |
| Start date | Dec 1, 2000 |
| First posted | Jan 7, 2004 |
| Last update posted | Oct 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: